FDA grants orphan-drug status for skin-disease treatment

07/29/2008 | Sydney Morning Herald (Australia), The

The FDA granted orphan-drug designation to Clinuvel Pharmaceuticals' afamelanotide as a treatment for erythropoietic porphyrias, a rare genetic disorder common in fair-skinned people. The orphan-drug status is a first for Clinuvel, which is developing afamelanotide to treat patients with ultraviolet-related skin diseases.

View Full Article in:

Sydney Morning Herald (Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory FDA
Cardinal Health
Columbus, OH
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA